General Atlantic LLC Akero Therapeutics, Inc. Transaction History
General Atlantic LLC
- $2.83 Billion
- Q3 2025
A detailed history of General Atlantic LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, General Atlantic LLC holds 5,733,989 shares of AKRO stock, worth $311 Million. This represents 9.63% of its overall portfolio holdings.
Number of Shares
5,733,989
Previous 5,733,989
-0.0%
Holding current value
$311 Million
Previous $306 Million
11.02%
% of portfolio
9.63%
Previous 10.64%
Shares
3 transactions
Others Institutions Holding AKRO
# of Institutions
302Shares Held
91.5MCall Options Held
1.05MPut Options Held
388K-
Janus Henderson Group PLC London, X06.28MShares$340 Million0.14% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$303 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$297 Million3.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$245 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.25MShares$230 Million0.04% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.52B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...